The six-transmembrane protein Stamp2 plays an important role in metabolically triggered inflammation and insulin action. We report that Stamp2 is expressed in human and mouse macrophages, is regulated upon differentiation or activation, acts as an anti-inflammatory protein, and regulates foam cell formation. Absence of Stamp2 results in significant increases in cellular NADPH levels, and both NADPH homeostasis and the exaggerated inflammatory response of Stamp2 À/À macrophages are rescued by exogenous wild-type but not by a reductase-deficient Stamp2 molecule. Chemical and genetic suppression of NADPH production in Stamp2 À/À macrophages reverts the heightened inflammatory response. Stamp2 is detected in mouse and human atherosclerotic plaques, and its deficiency promotes atherosclerosis in mice. Furthermore, bone marrow transplantation experiments demonstrated that Stamp2 in myeloid cells is sufficient to protect against atherosclerosis. Our data reveal a role of Stamp2 in controlling intermediary metabolites to regulate inflammatory responses in macrophages and in progression of atherosclerosis.
SUMMARY
The six-transmembrane protein Stamp2 plays an important role in metabolically triggered inflammation and insulin action. We report that Stamp2 is expressed in human and mouse macrophages, is regulated upon differentiation or activation, acts as an anti-inflammatory protein, and regulates foam cell formation. Absence of Stamp2 results in significant increases in cellular NADPH levels, and both NADPH homeostasis and the exaggerated inflammatory response of Stamp2 À/À macrophages are rescued by exogenous wild-type but not by a reductase-deficient Stamp2 molecule. Chemical and genetic suppression of NADPH production in Stamp2 À/À macrophages reverts the heightened inflammatory response. Stamp2 is detected in mouse and human atherosclerotic plaques, and its deficiency promotes atherosclerosis in mice. Furthermore, bone marrow transplantation experiments demonstrated that Stamp2 in myeloid cells is sufficient to protect against atherosclerosis. Our data reveal a role of Stamp2 in controlling intermediary metabolites to regulate inflammatory responses in macrophages and in progression of atherosclerosis.
INTRODUCTION
Metaflammation, the chronic, low-grade and metabolically orchestrated immune response at key metabolic organs, including adipose tissue, is a hallmark of obesity and contributes to related complications such as insulin resistance and beta cell dysfunction (Eguchi et al., 2012; Hotamisligil, 2006; Schenk et al., 2008; Shoelson et al., 2006) . Importantly, metabolic and inflammatory signals are tightly linked, and their coordinated action is important for the maintenance of metabolic homeostasis. This is best exemplified by the fact that both nutrients (such as glucose and lipids) and cytokines are able to activate inflammatory and stress signaling pathways like JNK, IKK, PKR, and others, leading to aberrant immune response, insulin resistance, beta cell dysfunction, metabolic dysregulation, and type 2 diabetes (Hotamisligil, 2006; Lumeng and Saltiel, 2011; Medzhitov, 2008) . There are also intimate interactions between metabolic and immune effectors at sites critical for metabolic homeostasis, such as macrophages and adipocytes in adipose tissue, Kuppfer cells and hepatocytes in liver, and many others, which are critical for metabolic regulation and chronic disease (Olefsky and Glass, 2010) . Since these cells also share many of the same molecules and networks that respond to nutrient-or pathogen-related signals, the proper function of this complex and highly integrated system requires proper control to maintain homeostasis, and these are not well understood.
The impact of nutrients on inflammatory pathways demands the existence of counterregulatory mechanisms to prevent overt inflammation or to mitigate stress upon physiological fluctuations in nutrient availability and transient surges at critical cells or organs. Recently, the six-transmembrane protein of prostate (Stamp)-2 was discovered as a potential molecule involved in such a role in adipose tissue (Wellen et al., 2007) . Stamp2, also known as TNF-induced adipose-related protein (TIARP) or six-transmembrane epithelial antigen of prostate 4 (STEAP4), belongs to a family of six-transmembrane proteins, termed either the STAMP or STEAP family. Three of the four family members, including Stamp2, were recently characterized as reductases (Ohgami et al., 2006) . Stamp2 is significantly regulated by fasting and feeding in visceral adipose tissue and was demonstrated to be required for normal metabolic homeostasis. Despite higher baseline levels, the nutritional regulation of Stamp2 in visceral adipose tissue is defective in obese models and total body Stamp2 deficiency leads to severe inflammation of visceral white adipose tissue and recapitulates features of the metabolic syndrome (Wellen et al., 2007) . These findings indicate a potential role for Stamp2 in the development of metabolic syndrome through its ability to integrate metabolic and inflammatory responses.
Stamp2 expression was recently shown to be increased in the joints and spleen of a mouse model of inflammatory arthritis (Inoue et al., 2009 ). In this model as well as in adipose tissue of human obese subjects, where basal expression level is regulated similar to mouse models, Stamp2 expression does, at least in part, colocalize or correlate with the macrophage marker CD68 (Arner et al., 2008) . Stamp2 expression has also been detected in circulating monocytes, and expression levels were reduced in humans with metabolic syndrome compared to healthy controls. Furthermore, decreased Stamp2 expression in these cells was inversely correlated with carotid plaque formation as determined by ultrasonography (Wang et al., 2010) . Hence, we postulated that Stamp2 may have a regulatory role in macrophages and could contribute to atherosclerosis, in which macrophage inflammatory responses play a critical role. Here, we report that Stamp2 controls inflammatory responses in macrophages by regulating intermediary metabolism and that its deficiency accelerates atherosclerosis. (A-C) Human THP-1 monocytes were treated with 100 ng/ml PMA or vehicle for indicated time points followed by assessment of Stamp2 mRNA (A) or protein expression (B and C) (n = 4-5). (D-F) Primary peritoneal macrophages were treated with LPS (100 ng/ml), Zymosan (50 mg/ml), or Poly I:C (50 mg/ml) followed by evaluation of Stamp2 mRNA (D) or protein expression (E and F) (n = 4-5). (G) IL-6 mRNA expression was assessed in primary WT and Stamp2 À/À macrophages at baseline and after treatment with LPS (10 ng/ml for 24 hr) (n = 6-8).
(H) IL-6 secretion into the culture medium by cells treated as in (G) was measured and normalized to cellular protein content (n = 9-12). Data are presented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 in Student's t test. Figures 1A-1C ). We next analyzed whether Stamp2 expression in macrophages was subject to regulation by inflammatory stimuli. We treated immortalized bone marrowderived mouse macrophages with the toll-like receptor (TLR) agonists Lipopolysaccharide (LPS), Zymosan, and Polyinosinic: polycytidylic acid (Poly I:C). All of these agents induced a strong increase of Stamp2 expression, both at the mRNA and protein levels ( Figures S1A-S1C ). In parallel experiments with primary peritoneal macrophages from wild-type (WT) mice, treatment with TLR agonists again induced a substantial increase of Stamp2 expression both in mRNA and protein levels ( Figures  1D-1F ). These data show that Stamp2 is expressed in both mouse and human macrophages and exhibits strong positive regulation during differentiation and by inflammatory stimuli.
RESULTS

Role of Stamp2 in
We then examined whether Stamp2 has a direct role in modulating the inflammatory response and analyzed expression of inflammatory cytokines in primary macrophages from Stamp2 À/À and WT mice. In these experiments, we observed significantly greater induction of IL-6, MCP-1, IL-1b, and TNF-a mRNA expression in Stamp2 À/À macrophages compared to WT cells after LPS treatment . In line with these observations, LPS-induced secretion of IL-6, MCP-1, IL-1b, and TNF-a into the culture medium was also significantly augmented in Stamp2 À/À macrophages compared to WT cells . Earlier studies have shown impaired insulin action and glucose transport in Stamp2 knockdown adipocytes and in Stamp2 À/À adipose tissue (Wellen et al., 2007) . Since insulin resistance in macrophages has been implicated in enhanced stress responses in these cells (Han et al., 2006) , we examined insulin-induced Akt phosphorylation. However, we detected no differences in the insulin responsiveness of Stamp2 À/À and WT macrophages ( Figures S1J and S1K ). Taken together, these data indicate that macrophages lacking Stamp2 expression are prone to an enhanced inflammatory response, but unlike adipocytes, they do not exhibit decreased insulin sensitivity.
Mechanisms Underlying the Overt Inflammatory Phenotype of Stamp2 Deficiency
Expression of inducible nitric oxide synthase (iNOS) increases during macrophage activation. As shown in Figures 2A-2C , iNOS mRNA and protein expression were enhanced to a significantly greater extent in Stamp2 À/À macrophages compared to WT cells upon treatment with LPS. In this setting, LPSinduced cellular release of NO into the culture medium was 
. Regulation of iNOS Expression and NO Production by Stamp2
(A-C) Expression of iNOS was detected at the mRNA (A) and protein level (B and C) in primary WT and Stamp2 À/À macrophages treated with LPS (10 ng/ml for 24 hr) (n = 6-10).
(D) NO production was measured in culture medium from cells treated with LPS (10 ng/ml) for 24 hr normalized for cellular protein content (n = 11).
(E) Primary peritoneal macrophages were treated with the iNOS inhibitor W1400 (10 mM) and 2 hr later stimulated with LPS (100 ng/ml for 4 hr) followed by assessment of IL-6 mRNA expression (n = 4). significantly higher in Stamp2-deficient macrophages ( Figure 2D ). This led us to consider NO production by iNOS as a mechanism by which Stamp2 regulates inflammatory responses. We treated Stamp2-deficient macrophages with a highly iNOS-specific inhibitor, W1400 (Fedorov et al., 2003) . Interestingly, inhibition of iNOS had no effect on LPSinduced expression of IL-6 in Stamp2
and WT macrophages ( Figure 2E ), illustrating that the changes in iNOS expression cannot account for the enhanced inflammatory response in Stamp2 À/À macrophages.
This led us to examine causality of defective Stamp2 function for the proinflammatory phenotype seen in macrophages by reintroducing full-length Stamp2 back into Stamp2 À/À macrophages. As Stamp2 possesses an oxidoreductase domain that may serve an enzymatic function, we also added back an oxidoreductase-deficient mutant form of Stamp2 (Stamp2
DN
). As shown in Figure 2F , this approach led to comparable expression of either Stamp2 or Stamp2 DN in Stamp2 À/À macrophages.
Furthermore, re-expression of wild-type Stamp2 dampened the LPS-induced proinflammatory gene expression in Stamp2
À/À cells ( Figure 2G ), demonstrating the causal role of Stamp2 for the observed phenotype. In contrast, oxidoreductase-deficient Stamp2 DN did not exhibit a similar ability to suppress inflammation ( Figure 2G ). Based on these findings, we concluded that the oxidoreductase domain of Stamp2, and the activity it possesses, is critical for Stamp2's ability to dampen inflammation. Next, we investigated the potential role of the oxidoreductase activity of Stamp2 in the control of the inflammatory response. In fact, the oxidoreductase domain of Stamp2 features a Rossman Fold homology sequence that is largely conserved across species and is predicted to bind to NADPH ( Figure 3A , top insert). This raises the possibility that Stamp2 utilizes NADPH for reductive catalysis and may be implicated in the regulation of cellular NADPH homeostasis. Therefore, we measured NADPH levels in Stamp2 À/À and WT primary peritoneal macrophages.
As shown in Figure 3A , Stamp2 À/À macrophages had significantly higher levels of cellular NADPH compared to WT controls. Given the role of NADPH in inflammatory processes, we then postulated that this excess NADPH availability could be fueling the overt inflammatory phenotype observed in Stamp2 deficiency. To test this hypothesis, we genetically and pharmacologically inhibited the primary NADPH-producing enzyme glucose 6-phosphate dehydrogenase (G6PDx) in Stamp2 À/À cells.
Chemical inhibition with dehydroepiandrosterone (DHEA) decreased NADPH levels ( Figure S2A ), was not cyto-or proteotoxic ( Figures S2B and S2C) , and essentially completely blocked LPS-induced IL-6 expression in Stamp2 À/À macrophages (Figure 3B) . To complement the chemical approach, we also targeted G6PDx genetically by RNA interference. This approach resulted in reduced G6PDx both at the mRNA and protein levels (Figures 3, S2D , and S2E) and also significantly reduced LPS- (B-D) G6PDx was inhibited in primary peritoneal macrophages by 50 mM DHEA followed by LPS treatment (100 ng/ml) and assessment of IL-6 mRNA expression (B). RNA interference directed against G6PDx gene resulted in >70% knockdown of the gene (C). IL-6 mRNA expression was assessed 24 hr after siRNA-induced knockdown of G6PDx and after LPS treatment (D) (n = 3).
(E) Primary peritoneal macrophages from Stamp2 À/À mice were electroporated as in Figures   2E and 2F, followed by analysis of NADPH levels (n = 4-5).
(F and G) Primary peritoneal macrophages were treated with LPS or vehicle followed by western blot analyses of the expression of phosphorylated and total proteins. (H and I) Cell lysates as in (F) were used to prepare nuclear and cytosolic fractions followed by western blot analyses of NMRAL1 expression and Lamin A/HSP90 expression as loading controls (n = 4). Data are presented as means ± SEM, *p < 0.05, in Student's t test.
induced IL-6 expression in Stamp2
À/À macrophages ( Figure 3D ). To assess a direct role for Stamp2 in this regulatory mechanism, we also tested whether we could rescue the elevated NADPH levels in Stamp2 À/À macrophages by reconstituting Stamp2 back into these cells. As shown in Figure 3E , re-expression of WT Stamp2 in Stamp2 À/À macrophages caused a significant reduction in NADPH levels, which did not occur when oxidoreductase-deficient Stamp2 DN was intro-
duced. These data demonstrate that Stamp2 regulates NADPH levels in macrophages, and this regulatory mechanism may be critical for the control of inflammatory responses. Next, we examined whether and which inflammatory signaling pathways were altered in Stamp2 À/À macrophages and evaluated phosphorylation of the MAP kinases ERK, JNK, and p38. We found increased LPS-induced phosphorylation of p38 in Stamp2 À/À cells compared to WT, whereas phosphorylation of ERK and JNK was not altered ( Figures 3F, 3G , S2F, and S2G). As p38 activation is frequently associated with increased signaling via NF-kB in immune cells, we also determined phosphorylation of p65. As shown in Figures 3F and 3G , LPS induced phosphorylation of p65 to a significantly greater extent in Stamp2 À/À cells compared to WT, potentially explaining the proinflammatory phenotype. In contrast, there were no differences in TLR4 expression. It has been reported that when cellular NADPH levels are low, the NADPH sensor protein NMRAL1 (NmrA-like family domain-containing protein 1) translocates to the nucleus and targets p65 for degradation and furthermore releases COMMD1 (copper metabolism gene MURR1 domaincontaining protein 1) to inhibit NF-kB (Lian and Zheng, 2009; Zheng et al., 2007) . As this protein may link increased NADPH levels to the proinflammatory phenotype, we determined regulation of NMRAL1 in cytosolic and nuclear fractions in Stamp2 À/À cells. As shown in Figures 3H and 3I , nuclear translocation of NMRAL1 was significantly decreased in LPS-treated Stamp2
À/À cells compared to WT controls. These results indicate that Stamp2's anti-inflammatory properties are dependent upon regulation of NADPH metabolism by its oxidoreductase activity, which engages inflammatory pathways. Our data also identify at least one potential mechanism of controlling inflammatory signaling through the NADPH sensor protein NMRAL1.
Role of Stamp2 for Macrophage Foam cell Formation
Loading of macrophages with modified lipids may promote foam cell formation and also influence the inflammatory responses. Hence, we assessed expression of IL-6 and TNF-a, as well as NO production, in cells after exposure to oxLDL (Figures S2H-S2J), and in this setting Stamp2 À/À macrophages also exhibited higher levels of these mediators compared to WT cells. Using thioglycollate-elicited primary macrophages we also detected a significant increase of foam cell formation due to Stamp2-deficiency ( Figures S3A and S3B ). We verified these results by loading cells with DiI-labeled oxLDL particles, followed by quantification of fluorescence intensity of the lysates normalized for protein concentration (Devaraj et al., 2001 ) ( Figure S3C ). We also examined the in vivo relevance of these observations in an established macrophage transfer model (Li et al., 2004) where thioglycollate-elicited primary macrophages were injected into the peritoneal cavity of ApoE À/À mice kept on Western diet for 6 weeks prior to the experiment. Three days later, macrophages were recovered and stained with oil red O. In this setting, foam cell formation of Stamp2 À/À macrophages was higher compared to WT cells ( Figures S3D and S3E ), confirming the in vivo relevance of our findings. As macrophage inflammation is associated with disturbed cholesterol clearance Khovidhunkit et al., 2003) , we assessed macrophage efflux of radiolabeled cholesterol. As shown in Figure S3F , Stamp2 À/À macrophages showed decreased cholesterol efflux and, consistent with this phenotype, exhibited a significant decrease in the expression of the ABC transporters ABCA1 (Figures S3G-S3I ) and ABCG1 ( Figures S4J-S4L ). In contrast, scavenger receptor CD36 and SR-A expression was similar between genotypes (data not shown). These findings show that foam cell formation of Stamp2 À/À macrophages was enhanced, most likely due to impaired cholesterol efflux secondary to decreased expression of ABC transporters. Together with the enhanced inflammatory properties of Stamp2 À/À macrophages, these data point toward a potential role of Stamp2 during atherogenesis.
Deficiency of Stamp2 Promotes Early Atherosclerosis in ApoE
-/-Mice If macrophage Stamp2 plays a role in atherosclerosis, expression of the protein within the vascular lesion may be anticipated. Indeed, Stamp2 was expressed in both human ( Figure 4A ) and mouse ( Figure 4B) (Figures 4C-4E) . Similarly, atherosclerotic lesions in the proximal aortas were larger in Stamp2 (Figures 4D and 4F ). In line with our observations in cultured macrophages, lesional inflammation, as assessed by staining for TNF-a and IL-6, was higher in sections from Stamp2 Figures S4D and S4E ), whereas assessment of macrophage cell count/lesion area (not shown), smooth muscle cell staining, and van Giesson staining revealed no significant differences ( Figure S4F ). We also measured inflammatory cytokine levels in the serum of both groups and were able to detect TNF-a and CXCL1. While there was no difference in CXCL1 levels between groups, there was a small but statistically significant increase in serum TNF-a levels of Stamp2 À/À ApoE À/À mice ( Figure S4G ). Since the changes are rather minor, our observations support a role for Stamp2 in local, rather than systemic, inflammatory changes in this setting. Taken together, these data support a role for macrophage Stamp2 during atherogenesis. However, in the whole organism, other cells and tissues may have also contributed to the phenotype. To address this, we performed bone marrow transplantation experiments to assess whether Stamp2 deficiency in bone marrow-derived cells is sufficient to induce early atherosclerosis. We transplanted bone marrow collected from Stamp2 À/À ApoE À/À mice or from ApoE À/À littermates to lethally irradiated 6-week-old ApoE À/À mice (n = 11 and n = 12, respectively). After 4 weeks on chow diet post engraftment, recipient mice were challenged with Western diet, and reconstitution with donor bone marrow was verified by the representation of donor alleles ( Figure 4G ). There were no significant differences in body weight, blood glucose levels, total serum cholesterol or triglycerides, and lipoprotein distribution between groups ( Figures S4H and S4I ). In the en face preparations, the extent of total atherosclerotic lesion area was significantly higher in the mice that received Stamp2
À/À ApoE À/À bone marrow compared to mice that were reconstituted with ApoE À/À cells ( Figures 4H and 4J) . Furthermore, lesion area in this group was also significantly higher in the histological analysis of proximal aortic sections, as confirmed by staining with oil red O and MOMA-2 ( Figures 4I  and 4K ). These data indicate an important role of Stamp2 during the development of atherosclerosis through its function in bone marrow-derived cells.
DISCUSSION
In this study, we demonstrate that Stamp2 deficiency results in an aggravated inflammatory response and increased foam cell and plaque area in the aortic root sections (F) (n = 8-12). Genotyping results of blood from ApoE À/À /ApoE À/À and STAMP2
together with a tail DNA sample from a Stamp2 +/À mouse as control (''Het Control''). The upper band depicts the Stamp2 À/À allele, whereas the lower band
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Stamp2 Controls Inflammation through Regulating NADPH formation in macrophages and accelerates atherosclerosis in vivo. The ability of Stamp2 to regulate inflammatory responses in macrophages is dependent on its NADPH oxidoreductase activity, and chemical or genetic inhibition of primary NADPHproducing enzyme G6PDx can rescue the phenotype caused by Stamp2 deficiency. These findings place Stamp2 in a vital position for cellular NADPH catalysis, which is critical for control of immune responses and may have important implications for human disease. In fact, it has been reported that lower cellular NADPH levels due to mutations in the human G6PDx gene can dampen inflammatory responses in mononuclear cells isolated from these subjects (Sanna et al., 2007) , and humans and mice with G6PDx deficiency appear to be protected against atherosclerosis (Cocco et al., 1998; Matsui et al., 2006) . We detected Stamp2 expression in macrophages of both mouse and human atherosclerotic plaques. Interestingly, decreased Stamp2 expression is evident in circulating monocytes of humans with cardiometabolic syndrome, and expression levels were inversely correlated with carotid atherosclerosis (Wang et al., 2010) . Hence, as a critical regulator of NADPH metabolism, inflammation, and atherosclerosis, Stamp2 may also play a critical role in human cardiovascular disease in general and promote disease particularly in the context of insulin resistance and diabetes. Stamp2 serves critical functions at the interface of metabolic and inflammatory pathways through its actions in target cells critical for metabolic and immune regulation. However, there are differences in the function of Stamp2 in adipocytes and macrophages. Notably, ablation of Stamp2 in cultured or primary adipocytes leads to decreased insulin action and glucose transport (Wellen et al., 2007) . However, in the experimental model used in the current study, this was not the case in macrophages. In an atherogenic background, systemic glucose tolerance was also not impaired in Stamp2-ApoE double-deficient mice. Although it is possible that ApoE deficiency may have at least partially masked potential Stamp2-related effects, these results indicate a more direct role of Stamp2 in the control of macrophage inflammatory responses in a dyslipidemic environment. This is consistent with earlier observations in another model, where the impact of atherosclerosis has also been independent of the effects of aP2 on systemic insulin action, which acts on both adipocytes and macrophages Makowski et al., 2001 ). It will be interesting to explore the potential cell autonomous effects of Stamp2 on other metabolically critical targets, such as hepatocytes or the central nervous system, in the future.
An important role of Stamp2's oxidoreductase domain was evident for regulation of cellular NADPH levels and inflammatory output of macrophages. These metabolic and immune functions may also have relevance beyond atherosclerosis and influence other disease states such as tumorigenesis. For example, Stamp2 expression is regulated by androgens, and Stamp2 is overexpressed in androgen receptor-positive prostate cancer cell lines where it contributes to increased growth and colony formation (Korkmaz et al., 2005) . These regulatory patterns may also be the result of Stamp2's role in altered cellular metabolism in tumor cells, where proliferating cells may need an increased expression of Stamp2 to meet the increased demand for nutrients. Inflammatory changes are also commonly associated with cancers and influence the progression and outcomes. Whether tumor formation and/or tumor inflammation are also controlled by Stamp2 and whether this molecule contributes to increased tumor incidence seen in obesity remain interesting future areas of investigation. Nonetheless, the function of Stamp2 as a regulatory protein of NADPH homeostasis and inflammatory responses opens up possibilities of its involvement in several pathological settings and indicate that Stamp2 may represent a suitable target for pharmacological intervention targeting cancer, metabolic, or cardiovascular diseases.
EXPERIMENTAL PROCEDURES
Animal Studies
Animal care and experimental procedures were performed with approval from animal care committees of Harvard University. Generation of Stamp2 À/À and wild-type mice and backcrossing to the C57BL/6 background were performed as described previously (Wellen et al., 2007) . Mice homozygous for the inactivation of Stamp2 were intercrossed with ApoE À/À mice also in the C57BL/6 background (Jackson Laboratories) to generate mice heterozygous at both loci. These Stamp2 Research Diets) ad libitum, beginning at 6 weeks of age. Before and after treatment, blood samples were collected from animals after 6 hr of food withdrawal, and the glucose tolerance test was performed by intraperitoneal glucose injection (1.5 g/kg) on conscious mice after overnight (15 hr) food withdrawal after 5 weeks of Western diet (7 weeks in bone marrowtransplanted mice).
Bone Marrow Transplantation
Six-week-old recipient mice were lethally irradiated with two 5 Gy doses (total 10 Gy) from a cesium source at a 4 hr interval in order to minimize radiation toxicity. Bone marrow was collected by flushing the femurs and tibiae from sex-matched donor mice (6-8 weeks of age) with phosphate-buffered saline (PBS). Each recipient mouse was injected with 4 3 10 6 bone marrow cells in 0.2 ml PBS into the retro-orbital venous plexus. During 1 week before and 4 weeks following bone marrow transplantation (BMT), 100 mg/l neomycin and 10 mg/l polymyxin B sulfate were added to the drinking water as described (Vallerie et al., 2008) .
Assessment of Atherosclerosis and Immunohistochemistry
Perfusion fixation, preparation of aortas and quantification of atherosclerotic lesions were performed as described . En face pinned aortas were stained with Sudan IV. The heart with the proximal aorta was embedded in OCT (Sakura Finetek) and snap frozen in 2-methylbutane. Lesions in the proximal aorta from serial 8 mm thick cryosections were stained with oil red O and counterstained with hematoxylin. Images of the aortas and immunohistochemistry slides were captured with a digital color camera (DP70; Olympus) mounted on a microscope. All quantitative analysis of images were performed using ImageJ software, and immunohistochemistry was performed as described with the indicated antibodies (Erbay et al., 2009; Furuhashi et al., 2007) . Human aortic lesions were collected from 4 male patients and 1 female represents the WT allele (G). Representative Sudan IV-stained pinned out en face preparations of aortas from ApoE À/À /ApoE À/À and Stamp2 
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Stamp2 Controls Inflammation through Regulating NADPH patient, ages ranging from 57-72, fixed in 10% formalin and paraffin embedded until further processing. At the time of immunostaining, serial sections were deparaffinized and stained using Stamp2 or CD68 antibody, following a citrate buffer epitope retrieval step, and visualized with DAB. Van Giesson and dehydroethidium staining (Zanetti et al., 2005) and biochemical assays were performed as described .
Examination of Macrophage Cytokine and Nitric Oxide Production
Supernatants from primary macrophages treated with LPS (Sigma) as indicated were evaluated for the production of IL-6, MCP-1, and TNF-a by ELISA (R&D), and IL-1b by electrochemiluminescence (MesoScale Discovery). The iNOS inhibitor W1400 (Cayman Chemical) was used at a concentration of 10 mmol/l. Supernatants of macrophages treated as described above were evaluated for nitric oxide production utilizing the Griess reaction with a commercial system (Invitrogen). Cytokine and nitric oxide levels were normalized to cellular protein content.
NADPH Measurements
The protocol used was adapted from a previous publication (Zhang et al., 2000) . Briefly, cells were lysed, and pyridine nucleotides were liberated from cells with two freeze-thaw cycles followed by sonication. After pelleting and removal of cell debris by centrifugation, absorbance was measured using a NanoDrop 2000 (ThermoScientific) at 340 nm to measure NADPH + NADH. All of the NADPH was converted to NADP+ using glutathione in the presence of oxidized GSSH, and absorbance was measured at 340 nm to determine total NADH. NADPH was calculated by subtracting NADH from NADPH + NADH, and levels were normalized to total protein content.
Statistical Analysis
Experimental results are shown as means ± SEM. Mean values for biochemical data from each group were compared by Student's t test. Data on vascular lesions, which were not normally distributed, were analyzed with a nonparametric Mann-Whitney test. Comparisons between time points were analyzed using repeated-measures analysis of variance, ANOVA. All statistical tests with p < 0.05 were considered significant.
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